What Avamigran Treats: Main Uses and Benefits

Avamigran is utilized as a specialized medicine for acute intervention in specific, severe symptom patterns, and is applied in settings where other supportive symptomatic relief has been insufficient. The combination is considered relevant in the symptomatic management of vascular headache, including migraine variants and cluster headache.

---

Its use is focused on managing established, disruptive episodes of moderate to severe vascular headaches. It is commonly used to help address symptom clusters that may become intense or disruptive in conditions presenting with acute episodes, relevant in conditions such as classic migraine, common migraine, and cluster headache. In a specialized clinical application, it may also assist in supporting functional stability related to specific orthostatic symptoms in select patients with autonomic failure.

The primary symptomatic benefit is that patients may access support that may contribute to easing the impact of the acute episode when symptoms are more pronounced, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Acute Pain	Description
Primary Context	Acute Intervention for Episodic Symptoms
Symptom Focus	Intense, Pulsating Headache Pain
Core Benefit	Provides Support for Difficult Symptoms

Regulatory References

1. NIH DailyMed overview

Who Can and Cannot Use Avamigran?

Avamigran (Ergotamine/Caffeine) is highly restricted due to the serious risks associated with ergotamine's potent vasoconstrictive (blood vessel constricting) effects. Eligibility is strictly defined by regulatory contraindications and patient characteristics.

Contraindicated Populations	Special Condition-Based Exclusions
Pregnancy/Lactation (Absolute prohibition)	Vascular Disease: Coronary Heart Disease (CHD), peripheral vascular disease, uncontrolled hypertension, history of stroke, or TIA.
Hypersensitivity to ergot alkaloids or caffeine	Severe Organ Impairment: Severe hepatic (liver) or renal (kidney) dysfunction.
Age Restriction (Use not established)	Concomitant Drug Use: Taking potent CYP3A4 inhibitors (e.g., certain antibiotics or HIV protease inhibitors).

Age and Administration Rules:

• Pediatric Population: Use is not recommended in children or adolescents under 18 years of age as safety and efficacy have not been established.
• Geriatric Population: Use in patients over 65 years is generally not recommended due to limited data and increased risk.
• Restriction: The medicine is intended only for the acute treatment of migraine attacks and must not be used for prevention or chronic daily administration.

Avamigran’s official interaction profile is defined by risks related to drug clearance and additive vascular effects. Co-administration with specific medications is strictly contraindicated due to the high risk of acute ergot toxicity, or ergotism, which is associated with intense vasoconstriction.

The primary pharmacokinetic interaction involves substances that inhibit the CYP3A4 enzyme, which is responsible for metabolizing the ergotamine component. Potent CYP3A4 inhibitors, including specific macrolide antibiotics (e.g., erythromycin) and certain azole antifungals (e.g., ketoconazole), are prohibited as they significantly increase ergotamine plasma concentrations.

The key pharmacodynamic interaction risk involves other vasoconstrictive agents. Co-administration with Triptans (5-HT1B/1D agonists) or other ergot-type drugs is contraindicated to prevent severe additive vasospasm. Regulatory documents mandate a 24-hour separation between the last dose of a Triptan and the administration of Avamigran.

Furthermore, nicotine exposure and the consumption of grapefruit juice are officially documented as potential interactions that may heighten the vasoconstrictive risk or increase exposure. Finally, the product is contraindicated in patients with severely impaired hepatic function, as compromised liver clearance significantly raises the risk of toxicity and adverse interactions.

Dual-Action Vasoconstriction via Serotonin and Adenosine

Avamigran works by modulating two distinct, interrelated systems—the serotonin receptors that control blood vessel diameter and the adenosine receptors that influence vascular tone, providing a dual-action mechanism to interrupt acute pathophysiological processes. Ergotamine acts as an agonist on serotonin 5-HT1 B receptors located on blood vessel walls, causing them to constrict. This action is reinforced by Caffeine, which blocks adenosine receptors ( A1 and A2 A), reversing the natural dilating influence of adenosine. This synergistic interaction achieves a pronounced physiological change in the extracerebral cranial circulation.

---

Modulating the Neurogenic Pain Cascade

This mechanism focuses on the neural component of the headache process. Ergotamine activates serotonin 5-HT1D receptors found on the nerve terminals of the trigeminal system. This molecular action leads to the presynaptic inhibition of vasoactive neuropeptides like CGRP, which are mediators of local inflammation. By suppressing the release of these mediators, the drug modulates the peripheral inflammatory cascade, modulating activity within the neurovascular pathway.

How to Use Avamigran: Official Administration Guidelines

Avamigran (Ergotamine and Caffeine) is utilized solely for acute, intermittent management and is not intended for chronic daily administration. The medicine is designed to be taken at the first sign of an acute episode, defining its use as an abortive therapy rather than a preventive regimen.

---

Administration Routes and Standard Dosing

The medicine is officially administered via the oral route as a tablet (ergotamine 1 mg / caffeine 100 mg). An alternative administration route approved in some regions is the rectal suppository.

Usage Constraint	Oral Tablet Regimen (Ergotamine 1 mg / Caffeine 100 mg)	Rectal Suppository Regimen
Initial Dose	2 tablets at onset of attack	1 suppository at onset of attack
Subsequent Dose	1 additional tablet every 30 minutes, if necessary	1 additional suppository after 1 hour, if necessary
Maximum Dose per Attack	6 tablets (6 mg ergotamine)	2 suppositories (4 mg ergotamine)
Maximum Weekly Dose	10 tablets (10 mg ergotamine)	5 suppositories (10 mg ergotamine)

---

Procedural and Population Constraints

The usage protocol dictates that the dose may be escalated only after the initial administration and must always remain within the strict attack-specific and weekly dose maximums to limit cumulative exposure. Safety and efficacy for the Ergotamine-Caffeine combination have not been established for use in the pediatric population. Patients should be aware of official instructions regarding the avoidance of certain foods, such as grapefruit, during use.

Research Evidence / Overview of Studies for Avamigran

This section summarizes the structure of available official research for the Ergotamine/Caffeine combination, focusing solely on the types of studies conducted, the populations included, and what findings was explored in the studies. The information is designed to provide context on the evidence landscape, not individual medical advice or treatment expectations. The findings describe group patterns, not personal outcomes.

Evidence for Acute Treatment of Migraine Headaches

Research into this combination primarily centers on its use for conditions associated with acute or disruptive episodes, such as migraine. The evidence base includes short-term, controlled trials—often Randomized Controlled Trials (RCTs)—which included adult patients experiencing headaches of moderate to severe intensity. These trials research examined a set of acute outcomes related to physical discomfort, including pain severity and the resolution of the attack within a few hours.

The studies monitored measured outcomes related to headache status at two hours post-dose and examined whether that status was maintained over the subsequent 24 hours. Research has also explored changes in associated symptoms, such as nausea and sensitivity to light or sound. It is important to note that the primary clinical evidence is limited by the age of many of the core trials, and comparative evidence is limited when exploring research that includes other antimigraine treatments.

Evidence for Other Vascular Headaches

Research for other specific conditions characterized by fluctuating or episodic manifestations, including cluster headaches, is limited and data remain insufficient compared to the volume of controlled research available for acute migraine. Instead, the available evidence often relies on small case series and clinical experience that research describes the observed responses in patients.

Research Gaps and Areas of Uncertainty

A significant limitation is the reliance on older clinical evidence, which leads to varying evidence quality across studies. Additionally, the follow-up durations were limited in most core research, meaning long-term effects are not fully established. Data for certain groups, particularly children and older adults, also remain insufficient.

Key Studies & References

1. Ergotamine Tartrate and Caffeine Tablets, USP (NIH DailyMed Overview)
2. Ergotamine and Caffeine (NIH MedlinePlus Drug Information)

Common questions about Avamigran (FAQ)

Q: How quickly does Avamigran usually start to work after a person takes it?

Official product information indicates that the active ingredient in Avamigran reaches its peak concentration in the bloodstream approximately two hours after the oral tablet is taken. This measurement marks the time when the drug is most concentrated in the body following administration.

Q: How long can the intended effects of Avamigran be expected to last?

While the overall duration of the headache-relieving effect is not explicitly defined in official clinical documents, one of the active components, caffeine, has a plasma elimination half-life of around 3.5 hours. This figure describes the time it takes for half of that substance to be eliminated from the bloodstream.

Q: What are the official warning signs of a serious side effect from Avamigran that require attention?

Serious signs associated with poor circulation, known medically as ischemia or ergotism, are documented in official warnings. These signs can include the development of coldness, paleness, numbness, or pain in the hands or feet that may signal a serious medical issue. Weak pulses in the extremities are also noted as a potential indicator.

Q: Does Avamigran interact with common over-the-counter pain relievers?

Regulatory documents do not list a specific interaction between Avamigran and common non-opioid, over-the-counter pain relievers like ibuprofen or acetaminophen. However, official regulatory documentation advises caution regarding concurrent use of any medications.

Q: Can Avamigran be taken with caffeine-containing products?

Avamigran already contains caffeine, which is included to enhance the blood vessel-constricting (vasoconstrictive) effect of ergotamine. Because official labeling advises against combining the drug with other vasoconstrictors, official information suggests that the intake of additional substances with vasoconstrictive properties may be limited.

Q: Why is Avamigran sometimes prescribed instead of similar medications?

The dual-agent formulation of Avamigran is based on the idea that caffeine enhances the blood vessel-constricting effects of ergotamine. This combination allows for a pronounced physiological change while avoiding the necessity of increasing the ergotamine dosage itself.

Q: Why do some people experience a return of symptoms after the effects of Avamigran wear off?

According to official information, if the medication is used frequently or for a long duration, stopping its use may be associated with withdrawal symptoms. These symptoms are reported to include rebound headaches or the return of headache symptoms.

Q: What kind of monitoring is officially recommended for patients using Avamigran long-term?

For patients who have risk factors for coronary artery disease (CAD), regulatory documents indicate the importance of a full cardiovascular evaluation before starting therapy. Furthermore, patients may require ongoing, periodic cardiovascular evaluations, which could include the use of ECG monitoring.

Q: Does the official labeling mention specific changes to diet or lifestyle alongside Avamigran use?

Official patient counseling advises patients to limit their consumption of alcoholic beverages while taking the medication, and to avoid smoking or using nicotine products. Official warnings note that driving or operating machinery should be avoided until an individual understands the drug's effects.

Q: Does Avamigran commonly cause drowsiness or fatigue?

While official documents do not explicitly list drowsiness or general fatigue as common side effects, the labeling does include central nervous system (CNS) effects. These reported effects include dizziness and generalized weakness.

Q: Is it normal to feel tightness or heaviness in the chest after taking Avamigran?

Official reports of side effects include the possibility of precordial distress and general chest pain. Patients may perceive these sensations as a feeling of tightness or heaviness in the chest area.

Q: What should be done if a patient forgets to take a scheduled dose of Avamigran?

Official regulatory patient information describes a protocol for managing missed doses, which generally involves taking the dose when remembered unless the next scheduled dose is imminent, in which case the subsequent dose should not be doubled.

Q: Are there known risks associated with suddenly stopping the use of Avamigran?

According to official safety information, stopping the use of Avamigran after long-term or indiscriminate use carries a known risk. This cessation can lead to withdrawal symptoms, which are officially reported to include the occurrence of rebound headaches.

Q: Is the concurrent use of alcohol allowed while taking Avamigran?

Official patient counseling and labeling advises individuals to limit their consumption of alcoholic beverages while they are using Avamigran.

Q: Does Avamigran interact with antidepressant medications like SSRIs or SNRIs?

Co-administration of Avamigran with other medications that have serotonergic activity, such as serotonin reuptake inhibitors (SSRIs) used for depression, may increase a serious risk. This combination can potentiate the risk of developing a condition known as serotonin syndrome.

Q: Are there any known contraindications regarding herbal supplements and Avamigran?

Official labeling indicates that consultation with a healthcare provider is generally recommended before starting any new medications, including herbal supplements. This is noted due to the potential for the product to interact adversely with various substances.

Q: Does Avamigran carry a Black Box Warning from the FDA or similar bodies?

Regulatory agencies have mandated that the product labeling include the most serious type of warning, known as a Black Box Warning. This warning specifically addresses the risk of serious and life-threatening restricted blood flow (ischemia) when the medication is taken alongside potent CYP3A4 inhibitors.

Q: Is Avamigran considered a controlled substance?

According to official regulatory filings, the product containing ergotamine and caffeine is not classified as a controlled substance. This means it is not placed under a DEA Schedule for controlled drug monitoring.

Q: Is Avamigran available as a generic medicine?

The product containing the ergotamine and caffeine combination is approved for marketing in generic form. This approval occurred through an Abbreviated New Drug Application (ANDA) process, confirming its availability as a non-brand-name medicine.

Q: What is the official description of an Avamigran overdose?

The official description of an overdose includes a range of severe symptoms. These can include vomiting, blurred vision, seizures, or a sensation of pounding in the neck or ears. Signs of severely decreased blood flow in the arms or legs (such as pain, numbness, or coldness) are also listed.

Official Storage Requirements

Avamigran (ergotamine tartrate and caffeine tablets) must be stored at a Controlled Room Temperature between 20^circ and 25 C (68^circ to 77 F). The product must be kept in a tight, light-resistant container and protected from excess heat, moisture, and direct light, as required by the regulatory labeling. The medicine should be kept from freezing to maintain its stability.

Child Safety and Disposal

It is mandatory to store Avamigran in a location that is out of the reach of children. For disposal of unused or expired tablets, the preferred regulatory method is utilizing a drug take-back program. If this option is unavailable, the tablets must be removed from the container and mixed with an undesirable substance, then sealed in a bag and placed in the household trash, following official guidelines.